Form 4: Merit Medical Systems CEO Sells 10,000 Shares Under Pre-Arranged Trading Plan

Merit Medical Systems Inc.'s President and CEO, Fred P. Lampropoulos, sold 10,000 shares of common stock for approximately $95.19 per share on June 5, 2025, as part of a Rule 10b5-1 trading plan.

Summary

• Fred P. Lampropoulos, President and CEO, Director, and 10% Owner of Merit Medical Systems Inc. (MMSI), reported the sale of 10,000 shares of common stock.
• The transaction occurred on June 5, 2025, at a weighted average price of $95.19 per share, with prices ranging from $95.10 to $95.32.
• This sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance.
• Following the sale, Mr. Lampropoulos directly beneficially owns 1,046,028 shares of common stock.
• Additionally, he indirectly beneficially owns 7,734.258 shares through his spouse, 97,892 shares through a 401(k) Plan, and 90 shares through his spouse as custodian for a child.
• He also holds various non-qualified stock options, including 371,870 directly and 2,000 indirectly through his spouse, with exercise prices ranging from $37.71 to $70.58 and expiration dates up to March 1, 2030.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to an insider sale by the CEO, even though it was pre-planned. However, the significant remaining holdings and the nature of a 10b5-1 plan mitigate a strong negative interpretation.

Positives

• The sale was executed under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not based on immediate, non-public information, which can reduce concerns about opportunistic selling.
• Despite the sale, the CEO retains a substantial direct beneficial ownership of 1,046,028 shares, demonstrating continued significant alignment with shareholder interests.
• The CEO also holds a significant number of non-qualified stock options (371,870 directly and 2,000 indirectly), providing further incentive for long-term company performance.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be interpreted by the market as a signal that the insider believes the stock price may be at or near a peak, or that they are taking profits.
• The reduction in direct shareholding, while small relative to total holdings, represents a decrease in the CEO's direct equity exposure.

Risks

• Market perception risk: Insider sales, even when pre-planned, can sometimes lead to negative market sentiment or speculation about the company's future prospects, potentially causing short-term stock price volatility.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider transaction is specific to Merit Medical Systems Inc. and does not directly provide broader industry trends. However, insider sales are a common occurrence across industries, often for personal financial planning, especially when executed under Rule 10b5-1 plans.

Comparison to Industry Standards

• Insider sales under Rule 10b5-1 plans are a standard practice for executives to diversify their holdings and manage personal finances while adhering to insider trading regulations. This aligns with common corporate governance practices.
• The CEO's remaining direct and indirect beneficial ownership of over 1.15 million shares (excluding options) is substantial, indicating continued significant alignment with shareholder interests, which is generally viewed positively compared to executives who significantly reduce their holdings.
• The disclosure of the weighted average price and the range of prices for the sale is standard for Form 4 filings, providing transparency consistent with SEC requirements.

Stakeholder Impact

• Shareholders: The sale by the CEO could lead to minor concerns about management's confidence, but the pre-planned nature and substantial remaining holdings should temper significant negative reactions. Transparency is maintained through the Form 4 filing.
• Employees, Customers, Suppliers, Creditors: This specific transaction is unlikely to have a direct or immediate impact on these stakeholders, as it relates to personal financial planning of an executive rather than operational or strategic changes.

Next Steps

• The document does not specify any future actions, events, or milestones for the company or the reporting person beyond the reported transaction.

Key Dates

Recommendation

Keywords

Merit Medical Systems, MMSI, SEC Form 4, Insider Trading, Stock Sale, CEO, Fred P. Lampropoulos, Rule 10b5-1, Beneficial Ownership, Stock Options